Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle-Income Country, Turkey: Results of a Prospective Multicenter Study

ÖZMEN V., ÇAKAR B., GÖKMEN E., ÖZDOĞAN M., GÜLER N., URAS C., ...More

EUROPEAN JOURNAL OF BREAST HEALTH, vol.15, no.3, pp.183-190, 2019 (Peer-Reviewed Journal) identifier identifier

  • Publication Type: Article / Article
  • Volume: 15 Issue: 3
  • Publication Date: 2019
  • Doi Number: 10.5152/ejbh.2019.4761
  • Journal Name: EUROPEAN JOURNAL OF BREAST HEALTH
  • Journal Indexes: TR DİZİN (ULAKBİM)
  • Page Numbers: pp.183-190
  • Keywords: Early breast cancer, genetic profiling, oncotype-Dx, cost, markov model, QUALITY-OF-LIFE, RECURRENCE SCORE, CHEMOTHERAPY, TAMOXIFEN, ASSAY, RISK
  • Acibadem Mehmet Ali Aydinlar University Affiliated: Yes

Abstract

Objective: Breast cancer is a heterogenous disease, and genetic profiling helps to individualize adjuvant treatment. The Oncotype DX is a validated test to predict benefit of adjuvant systemic treatment. The aims of this study are to determine the costs of chemotherapy in government hospitals in Turkey and evaluate the cost-effectiveness of the Oncotype DX from the national insurance perspective.